Respicardia launches Remed ē system, taps Sommerness as CEO

Respicardia said today it launched its Remedē transvenous implantable neurostimulation system designed to treat patients with central sleep apnea, and that it named Peter Sommerness as CEO. The Remedē system consists of a surgically placed battery pack and thin wires inserted into the blood vessels in the chest near the phrenic nerve, which it stimulates to engage the diaphragm to restore natural breathing during sleep and improve patient quality of life and satisfaction. “Central sleep apnea is very common in cardiac patients, especially patients with heart failure, and is associated with a significantly greater risk for morbidity and mortality. Being able to treat CSA offers a new hope to improve the quality of life for my patients,” Dr. William Abraham of the Ohio State University Wexner Medical Center said in prepared remarks. The procedure treating the first patient was performed by Dr. Ralph Augostini at Columbus’ Ohio State University Wexner Medical Center, the Minnetonka, Minn.-based company said. “The Remedē System is a breakthrough technology that uniquely treats central sleep apnea while greatly improving a patient’s quality of life. I am proud to be a part of the system’s first U.S. commercial case that has the potential to become the standard of care for these patients,” Dr. Augostini said in a prepared statement. Prior to joining Respicardia, Sommerness served as a partner at McKinsey and Comp...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Neuromodulation/Neurostimulation Respiratory Respicardia Source Type: news

Related Links:

AbstractPurpose of ReviewAn abnormal heightened carotid body (CB) chemoreflex, which produces autonomic dysfunction and sympathetic overactivation, is the common hallmark of obstructive sleep apnea (OSA), resistant hypertension, systolic heart failure (HF), and cardiometabolic diseases. Accordingly, it has been proposed that the elimination of the CB chemosensory input to the brainstem may reduce the autonomic and cardiorespiratory alterations in sympathetic-associated diseases in humans.Recent FindingsA growing body of evidence obtained in preclinical animal models support that an enhanced CB discharge produces sympatheti...
Source: Current Hypertension Reports - Category: Primary Care Source Type: research
Obstructive Sleep Apnea (OSA) increases the risk of diastolic dysfunction and heart failure. The impact of OSA on hospitalization for heart failure with preserved ejection fraction (HFpEF) is not well elucidated. We used data from the National Inpatient Sample (NIS) for the years 2012 to 2014. We identified discharges (age ≥18 years) associated with OSA and HFpEF using ICD-9-CM codes (327.23 and 428.3x) respectively. Propensity score analysis, adjusting for age, sex, race and comorbidities, compared the rates of admission for HFpEF in patients with OSA to those without OSA.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
The spectrum of sleep-disordered breathing (SDB) ranges from mild snoring to obstructive sleep apnea, the most severe form of SDB. Current recommendations are to treat these women with continuous positive airway pressure despite limited data. SDB in early and mid-pregnancy is associated with preeclampsia and gestational diabetes. Pregnant women with a diagnosis of obstructive sleep apnea at delivery were at significantly increased risk of having cardiomyopathy, congestive heart failure, pulmonary embolism, and in-hospital death. These effects were exacerbated in the presence of obesity. Postpartum, these women are at risk ...
Source: Obstetrics and Gynecology Clinics - Category: OBGYN Authors: Source Type: research
Abstract Sleep-disordered breathing (SDB) is a risk factor for cardiovascular disease including acute coronary syndrome and acute myocardial infarction, and treating SDB prevents their development and recurrence and improves a patient's prognosis. Therefore, SDB is considered a therapeutic target for cardiovascular disease. In 2010, the Japanese Circulation Society published guidelines for the diagnosis and treatment of SDB in patients with cardiovascular disease. However, therapeutic intervention for patients with SDB was recently reported not to suppress the development or deterioration of cardiovascular disease...
Source: Journal of Nippon Medical School - Category: Universities & Medical Training Authors: Tags: J Nippon Med Sch Source Type: research
ConclusionCSA was associated with VT occurrence irrespective of sleep/wake status in HFrEF patients, and independently predicted the occurrence of VT. This association may contribute to chances by which CSA increases sudden death risk in HFrEF patients.
Source: Clinical Research in Cardiology - Category: Cardiology Source Type: research
Publication date: June 2018 Source:Obstetrics and Gynecology Clinics of North America, Volume 45, Issue 2 Author(s): Jennifer E. Dominguez, Linda Street, Judette LouisTeaser The spectrum of sleep-disordered breathing (SDB) ranges from mild snoring to obstructive sleep apnea, the most severe form of SDB. Current recommendations are to treat these women with continuous positive airway pressure despite limited data. SDB in early and mid-pregnancy is associated with preeclampsia and gestational diabetes. Pregnant women with a diagnosis of obstructive sleep apnea at delivery were at significantly increased risk of having cardi...
Source: Obstetrics and Gynecology Clinics of North America - Category: OBGYN Source Type: research
The incidence of new-onset atrial fibrillation (NOAF) is increasing both in the Asian populations and Western countries. Several demographic and clinical risk factors were independently associated with NOAF, including ageing, male sex, obesity, obstructive sleep apnea syndrome, hypertension, coronary artery disease, renal dysfunction and heart failure. However, some differences in the incidence of NOAF, the prevalence of some risk factors and lifestyle or environmental conditions may exist between Asian and Western countries.
Source: International Journal of Cardiology - Category: Cardiology Authors: Source Type: research
CONCLUSIONS: Portable sleep monitoring can accurately diagnose sleep apnea in hospitalized heart failure patients and may promote early initiation of treatment. PMID: 29684317 [PubMed - as supplied by publisher]
Source: Chest - Category: Respiratory Medicine Authors: Tags: Chest Source Type: research
AbstractPurpose of ReviewThe goal of this paper is to provide a summary of the new recommendations in the most recent 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. The intent is to provide the background and the supporting evidence for the recommendations and to provide practical guidance for management strategies in treatment of heart failure patients.Recent FindingsIn the 2017 ACC/AHA/HFSA Focused Update of HF ...
Source: Current Cardiology Reports - Category: Cardiology Source Type: research
In conclusion, high plasma s(P)RR levels are associated with left ventricular remodeling and, especially, with renal dysfunction. Therefore, s(P)RR is a promising evaluative indicator for the severity of HFrEF patients.
Source: Peptides - Category: Biochemistry Source Type: research
More News: Brain | Cardiology | Heart | Heart Failure | Neurology | Neuroscience | Respiratory Medicine | Sleep Apnea | Sleep Disorders | Sleep Medicine